Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 57

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 57
---
mination or Change in Control Regardless of the manner in which the executive officer’s service with us terminates, each of our named executive officers is or was, as applicable, entitled to receive amounts earned during his or her term of service, including unpaid salary, accrued unused vacation and any vested entitlements under any employee benefit plan. Pursuant to the employment agreements entered into with each of our named executive officers, each named executive officer is, or would have been, entitled to the following payments and benefits upon a qualifying termination of employment or a change in control. The terms of “cause,” “disability” and “good reason” are each defined in the respective amended and restated employment agreements. The severance provisions of each NEO’s employment agreement, as in effect as of December 31, 2024, are described in the paragraphs below. As noted above, Mr. Segal and Dr. Koehler each departed from the Company in early 2025, and the terms of the actual separation agreements that we entered into with them are described above under “Employment Arrangements with our Named Executive Officers—Segal Separation Agreement” and “—Koehler Separation Agreement.” If the executive officer is terminated by us involuntarily without “cause” and not due to death or “disability” or the executive officer resigns for “good reason,” in each case, not in connection with a “change in control” (each term as defined in the 2020 Plan), then:

| • |     | With respect to Mr. Segal, he would have been entitled to (1) cash severance equal to 12 months of base salary, paid in 12 equal monthly installments; (2) continued participation in our group insurance plans and employee benefits for 12 months; (3) accelerated vesting of his options that are subject to time-based vesting schedule that were scheduled to vest in the 12 months following the date of termination, and Mr. Segal’s vested options would have remained exercisable for up to 12 months following such termination; and (4) a lump sum payment equal to his target bonus pro-rated for the year of termination. |

| • |     | Dr. Koehler would have been, and Dr. Zinda would be, entitled to (1) cash severance equal to seven months of base salary, paid in seven equal monthly installments; (2) payment of COBRA premiums for up to seven months; and (3) accelerated vesting of the